Duravyu™ Wet AMD Trials Receive Third Consecutive Positive Safety Nod, Boosting Confidence Ahead of Topline Data
EYPT has more than doubled off its 52-week low of $5.3.
Summary
EyePoint announced its third consecutive positive recommendation from the Data Safety Monitoring Committee (DSMC) for its Phase 3 wet AMD trials for Duravyu™. The DSMC recommended the trials continue without modifications, citing a continued favorable safety profile. This positive clinical update follows recent negative financial news for EyePoint, including a significant increase in net loss and a sharp drop in Q1 2026 revenue, but reinforces earlier news that the pivotal Phase 3 trials remained on track. A third consecutive positive DSMC recommendation is a strong de-risking event for Duravyu™, significantly boosting confidence in the drug's safety profile ahead of crucial mid-2026 topline data. This reduces the likelihood of trial halts due to safety concerns and is a material positive catalyst for the company's primary pipeline asset. Investors will now keenly await the mid-2026 topline data for the Phase 3 trials, as this will be the next major catalyst determining the drug's commercial viability.
At the time of this announcement, EYPT was trading at $13.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $5.30 to $19.11. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.